丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究*

doi:10.3969/j.issn.1671-2587.2024.02.006

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (2): 187-195.DOI: 10.3969/j.issn.1671-2587.2024.02.006

丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究^*

陈鑫, 邵小宝, 薛昌雯, 周琳, 朱培元

南京中医药大学附属南京中医院输血科,江苏南京 210022

收稿日期:2024-01-03 出版日期:2024-04-20 发布日期:2024-04-23
通讯作者: 朱培元,主要从事中西医结合输血研究,（E-mail）zhupy@njucm.edu.cn。
作者简介:陈鑫,主要从事中西医结合临床与输血治疗工作,（E-mail）2516442792@qq.com。并列第一作者：邵小宝,主要从事临床输血工作,（E-mail）shaoxiaobao520@163.com。
基金资助:
*本课题受南京市卫生科技发展专项资金项目（No.YKK21195）、江苏省输血协会英科新创科研基金（No.JS2022006）资助

Experimental Study on Inhibition of the Interaction between Platelets and Tumor Cells by Tanshinone ⅡA

CHEN Xin, SHAO Xiaobao, XUE Changwen, ZHOU Lin, ZHU Peiyuan

Department of Blood Transfusion, Nanjing Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210022

Received:2024-01-03 Online:2024-04-20 Published:2024-04-23

摘要/Abstract

摘要： 目的探究丹参酮IIA（Tan ⅡA）抗血小板作用以及抑制人血小板与结肠癌HCT116细胞的相互作用。方法采用不同浓度Tan ⅡA（10、20、40 μmol/L）处理健康志愿者全血或血小板,通过血栓弹力图试验（TEG）检测二磷酸腺苷（Adenosine diphosphate,ADP）、花生四烯酸（arachidonic acid,AA）抑制率,流式细胞术检测血小板CD62P、PAC-1表达率,黏附试验检测Tan ⅡA处理后血小板与HCT116细胞的黏附情况,划痕试验检测Tan ⅡA处理后血小板对HCT116细胞的迁移能力的影响。结果 TEG结果表明,Tan IIA呈浓度依赖性抑制ADP、AA诱导的血小板聚集（P<0.01）,低浓度Tan ⅡA处理就能获得较好的ADP抑制率,为（73.48±19.63）%,高浓度Tan ⅡA才能获得较好的AA抑制率,为（78.20±18.58）%。流式细胞术结果显示,Tan ⅡA可以呈浓度依赖抑制凝血酶或ADP诱导的血小板表面CD62P、PAC-1表达（P<0.05）。黏附试验结果证实,Tan ⅡA能显著抑制凝血酶或ADP激活血小板与HCT116细胞之间的黏附作用,抑制能力与Tan ⅡA浓度呈正相关。划痕试验结果发现,活化血小板可促进HCT116细胞迁移,采用低浓度（10 μmol/L）Tan ⅡA处理血小板就可显著抑制肿瘤细胞的迁移。结论 Tan ⅡA可通过抑制血小板聚集和活化,进而抑制血小板与肿瘤细胞的相互作用。

关键词: 丹参酮ⅡA, 血小板, 肠癌, 活化, 迁移

Abstract: Objective To investigate the antiplatelet effect of tanshinone ⅡA (Tan IIA) and its inhibition effect of the interaction between human platelets and HCT116 cells of colon cancer. Method Whole blood or platelets of healthy volunteers were treated with different concentrations of Tan ⅡA (10, 20, 40 μmol/L), and inhibition rate of platelet aggregation triggered with Adenosine diphosphate (ADP) and arachidonic acid (arachidonic acid) were detected by TEG. The expression rates of CD62P and PAC-1 in platelets were detected by flow cytometry, the adhesion test was used to detect the adhesion of platelets to HCT116 cells after Tan ⅡA treatment, and the effect of platelets on the migration ability of HCT116 cells after Tan ⅡA treatment was tested by scratch test. Results The TEG results showed that Tan ⅡA inhibited ADP and AA-induced platelet aggregation in a concentration-dependent manner (P<0.01), low concentration Tan ⅡA treatment can obtain higher ADP inhibition rate, which is (73.48±19.63) %, high concentration Tan ⅡA treatment can obtain higher AA inhibition rate, which is (78.20±18.58) %. Flow cytometry detection showed that Tan IIA inhibited thrombin or ADP-induced expression of CD62P and PAC-1 on platelet surface in a concentration-dependent manner (P<0.05). Adhesion test results confirmed that Tan ⅡA could significantly inhibit the adhesion between thrombin or ADP-activated platelets and HCT116 cells, and the inhibition ability was positively correlated with Tan ⅡA concentration. The results of scratch test showed that activated platelets could promote the migration of HCT116 cells, and treatment of platelets with low concentration (10 μmol/L) Tan ⅡA could significantly inhibit promotion of platelet to the migration of tumor cells. Conclusion Tan IIA can inhibit the interaction between platelets and tumor cells by inhibiting platelet aggregation and activation.

Key words: Tanshinone ⅡA, Platelets, Bowel cancer, Activation, Transfer

中图分类号:

R285

陈鑫, 邵小宝, 薛昌雯, 周琳, 朱培元. 丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 187-195.

CHEN Xin, SHAO Xiaobao, XUE Changwen, ZHOU Lin, ZHU Peiyuan. Experimental Study on Inhibition of the Interaction between Platelets and Tumor Cells by Tanshinone ⅡA[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 187-195.

参考文献

[1] GAO A,ZHANG L L,ZHONG D S.Chemotherapy-induced thrombocytopenia:literature review[J].Discov Oncol,2023,14(1):10.
[2] GARRAUD O,HAMZEH-COGNASSE H,CHALAYER E,et al.Platelet transfusion in adults:an update[J].Transfus Clin Biol,2023,30(1):147-165.
[3] WANG J,ZHOU P,HAN Y W,et al.Platelet transfusion for cancer secondary thrombocytopenia:platelet and cancer cell interaction[J].Transl Oncol,2021,14(4):101022.
[4] SHI Q Y,JI T,TANG X D,et al.The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis[J].Cell Oncol (Dordr),2023,46(3):521-532.
[5] FALANGA A,RUSSO L,MILESI V,et al.Mechanisms and risk factors of thrombosis in cancer[J].Crit Rev Oncol Hematol,2017,118:79-83.
[6] 符丹丽,陈培丰.恶性肿瘤高凝状态的中西医发病机制[J].肿瘤防治研究,2018,45(3):179-182.
[7] 王伟军,程树群.实体瘤发生癌栓免疫逃避机制研究进展[J].中国实用外科杂志,2021,41(8):949-952.
[8] ZHOU L,ZHANG Z,TIAN Y Z,et al.The critical role of platelet in cancer progression and metastasis[J].Eur J Med Res,2023,28(1):385.
[9] YEUNG J,LI W J,HOLINSTAT M.Platelet signaling and disease:targeted therapy for thrombosis and other related diseases[J].Pharmacol Rev,2018,70(3):526-548.
[10] TAO D L,TASSI YUNGA S,WILLIAMS C D,et al.Aspirin and antiplatelet treatments in cancer[J].Blood,2021,137(23):3201-3211.
[11] HWANG B O,PARK S Y,CHO E S,et al.Platelet CLEC2-podoplanin axis as a promising target for oral cancer treatment[J].Front Immunol,2021,12:807600.
[12] 陶倩倩,张雷,杜晓鹂,等.血小板介导的肿瘤微环境调控:活血化瘀中药的新靶点[J].中南药学,2021,19(6):1212-1218.
[13] 田会茹,姜思琴,吕红,等.丹参注射液抑制血小板诱导的乳腺癌细胞体外转移作用[J].中国实验方剂学杂志,2023,29(21):79-85.
[14] 孙立东. 鸡血藤提取物通过阻断“肿瘤-血小板” 互作抑制结肠癌转移的药效和机制研究[D].北京:中国中医科学院,2022.
[15] 曹慧敏,吴瑾,贾连群,等.丹参酮ⅡA对心血管系统药理作用的研究进展[J].世界中医药,2017,12(7):1718-1722.
[16] 黄刚,周世恒,罗贵全,等.丹参酮ⅡA磺酸钠注射液对急性心梗患者血小板活化功能的影响[J].中西医结合心血管病电子杂志,2017,5(3):21-22.
[17] LIU H Y,LIU C Y,WANG M Y,et al.Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway[J].Sci Rep,2021,11(1):19268.
[18] ZHOU M G,ZHOU G J,HU S H,et al.Tanshinone IIA suppress the proliferation of HNE-1 nasopharyngeal carcinoma an in vitro study[J].Saudi J Biol Sci,2018,25(2):267-272.
[19] ZHOU L H,SUI H,WANG T,et al.Tanshinone IIA reduces secretion of pro-angiogenic factors and inhibits angiogenesis in human colorectal cancer[J].Oncol Rep,2020,43(4):1159-1168.
[20] NIE Z Y,ZHAO M H,CHENG B Q,et al.Tanshinone IIA regulates human AML cell proliferation,cell cycle,and apoptosis through miR-497-5p/AKT3 axis[J].Cancer Cell Int,2020,20:379.
[21] CHIU T L,SU C C.Tanshinone IIA increases protein expression levels of PERK,ATF6,IRE1α,CHOP,caspase-3 and caspase-12 in pancreatic cancer BxPC-3 cell-derived xenograft tumors[J].Mol Med Rep,2017,15(5):3259-3263.
[22] SHIH C C,CHAN M V,KIRKBY N S,et al.Platelet inhibition by P2Y₁₂ antagonists is potentiated by adenosine signalling activators[J].Br J Pharmacology,2021,178(23):4758-4771.
[23] RIBES A,GARCIA C,GRATACAP M P,et al.Platelet P2Y₁ receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment[J].BMC Biol,2023,21(1):14.
[24] ZHANG H,PAN D A,WU X Q,et al.Platelet protease activated receptor 1 is involved in the hemostatic effect of 20(S)-protopanaxadiol by regulating calcium signaling[J].Front Pharmacol,2020,11:549150.
[25] KÜNZE G,ISERMANN B.Targeting biased signaling by PAR1:function and molecular mechanism of parmodulins[J].Blood,2023,141(22):2675-2684.
[26] HUANG J S,LI X,SHI X F,et al.Platelet integrin αIIbβ3:signal transduction,regulation,and its therapeutic targeting[J].J Hematol Oncol,2019,12(1):26.
[27] LI H,JIANG W,ZHANG S R,et al.The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis[J].Oncogene,2023,42(18):1453-1465.
[28] HASCHEMI R,GOCKEL L M,BENDAS G,et al.A combined activity of thrombin and P-selectin is essential for platelet activation by pancreatic cancer cells[J].Int J Mol Sci,2021,22(7):3323.
[29] 胡谊容,田松明,赵福容.喉癌患者PAC-1、CD62P表达与临床病理特征和复发的关系[J].中国中西医结合耳鼻咽喉科杂志,2020,28(1):56-60.

丹参酮ⅡA抑制血小板与肿瘤细胞相互作用的实验研究^*

Experimental Study on Inhibition of the Interaction between Platelets and Tumor Cells by Tanshinone ⅡA

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	中国输血协会临床输血管理学专业委员会. 术前深度单采自体红细胞和/或血小板储血技术应用中国专家共识[J]. 临床输血与检验, 2024, 26(2): 145-155.
[2]	张雷英, 于洋. ABO不同型血浆输注的风险认知与临床实践进展[J]. 临床输血与检验, 2024, 26(2): 164-172.
[3]	谢慧晗, 邵小宝, 陈鑫, 周琳, 朱培元. 红景天苷用于单采血小板保存的研究^*[J]. 临床输血与检验, 2024, 26(2): 196-204.
[4]	薛昌雯, 邵小宝, 陈鑫, 周琳, 朱培元. 银杏内酯B抑制血小板与肿瘤细胞相互作用的实验研究^*[J]. 临床输血与检验, 2024, 26(2): 205-212.
[5]	严美玲, 朱培元. 基于网络药理学与分子对接探讨桃红四物汤对血小板活化的作用机制^*[J]. 临床输血与检验, 2024, 26(2): 213-222.
[6]	尚玮, 汪德清. 纤维蛋白原在创伤性大失血救治中的研究进展^*[J]. 临床输血与检验, 2024, 26(2): 274-281.
[7]	中国生物医学工程学会血液疗法与工程分会, 中国整形美容协会毛发医学分会, 富血小板血浆创新技术脱发治疗项目组. 自体单采富血小板血浆在脱发治疗中的临床应用专家共识^*[J]. 临床输血与检验, 2024, 26(1): 1-7.
[8]	阳雪新, 魏亚明. ABO非同型血小板输注的现状及建议^*[J]. 临床输血与检验, 2024, 26(1): 17-22.
[9]	阳雪新, 袁咏梅, 吴兆勇, 苑召虎, 刘珍, 童欣欣, 陈小卫, 魏亚明. ABO次侧不相合血小板输注的有效性和安全性初步研究^*[J]. 临床输血与检验, 2024, 26(1): 42-48.
[10]	陈岩, 陈麟凤, 何欣, 王岩, 于文娟, 刘璇, 刘思琪. 结直肠癌贫血患者围手术期用血影响因素分析: 一项单中心2013—2020年数据[J]. 临床输血与检验, 2024, 26(1): 79-85.
[11]	陈旭升, 杨永涛. 富血小板血浆凝胶在5例糖尿病患者难愈性植入物外露创面的临床应用[J]. 临床输血与检验, 2024, 26(1): 123-126.
[12]	张乃红, 蔡培飞, 刘夏, 李健, 费忠化. 自体血小板分离回输与异体血小板输注在急性A型主动脉夹层手术中的有效性比较^*[J]. 临床输血与检验, 2023, 25(6): 738-742.
[13]	李丽, 刘晓庆, 孙玉艾, 李松芯. 不同补钙方式对固定献血者血清Ca²⁺及PTH的影响分析[J]. 临床输血与检验, 2023, 25(6): 798-801.
[14]	乔剑, 刁春红, 于洋, 张娜, 常梦远. 吴茱萸碱通过调节HMGB1/TLR4/NF-κB信号通路减轻大鼠输血相关性急性肺损伤^*[J]. 临床输血与检验, 2023, 25(5): 599-606.
[15]	王笑欢, 郭凯, 刘倩, 牛子健, 王孟键, 郭婧, 马曙轩. 凝血和血小板功能分析仪在检测川崎病患儿不同时期凝血功能中的应用[J]. 临床输血与检验, 2023, 25(5): 607-612.